Stalicla Series B promised to propel precision neuro advances

Switzerland-based Stalicla, a biopharma advancing precision medicine pipelines for neuropsychiatric and neurological disorders, has announced the successful completion of the first closing of its Series B financing round, securing $17.4 million.

Led by SPRIM Global Investments, with key participation from core investors, this funding includes a $3.8 million credit facility.

"This financial backing underscores Stalicla's role as a trailblazer in the neuro precision space"Stalicla says that the proceeds will be used to prepare its pioneering precision autism spectrum disorder (ASD) Phase II trial, STP1, the establishment of its STP7 mGluR5 negative allosteric modulator (mGluR5 NAM) platform, including the launch of a Phase III study in substance use disorders supported by the National Institute on Drug Abuse, and the ramp up of its ongoing biosampling/ patient identification trial, STA-B-001.